Allogeneic therapies as a pathway to long-term scalability

Developing allogeneic cell therapies requires careful consideration of process design, donor selection, and quality systems to achieve reproducible and scalable manufacturing. This session highlights approaches to optimize yield, maintain product consistency, and enable efficient scale-up for broader patient access. 

Key takeaways 

• Explore process strategies that support scalable allogeneic therapy production 

• Discuss methods to maintain product consistency across batches 

• Evaluate donor selection and sourcing considerations for robust manufacturing 

• Identify approaches to integrate quality systems and control strategies 

• Review case examples demonstrating successful long-term scale-up